{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T20:50:09Z","timestamp":1770497409494,"version":"3.49.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004442","name":"Narodowym Centrum Nauki","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004442","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["2015\/17\/D\/NZ7\/00792"],"award-info":[{"award-number":["2015\/17\/D\/NZ7\/00792"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.xphs.2023.08.007","type":"journal-article","created":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T11:18:51Z","timestamp":1692184731000},"page":"2597-2603","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Improving the Safety of Clinical Management of COVID-19 Patients Receiving Aminoglycosides and Parenteral Nutrition: Y-site Compatibility Studies"],"prefix":"10.1016","volume":"112","author":[{"given":"Aleksandra","family":"Gosty\u0144ska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5986-7544","authenticated-orcid":false,"given":"Katarzyna","family":"Dettlaff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Jeli\u0144ska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5106-5937","authenticated-orcid":false,"given":"Maciej","family":"Stawny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2023.08.007_bib0001","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/cid\/ciaa530","article-title":"Bacterial and fungal coinfection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing","volume":"71","author":"Rawson","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.xphs.2023.08.007_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.mehy.2020.109984","article-title":"Aminoglycosides can be a better choice over macrolides in COVID-19 regimen: plausible mechanism for repurposing strategy","volume":"144","author":"Chalichem","year":"2020","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.xphs.2023.08.007_bib0003","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.jiph.2021.01.016","article-title":"Aminoglycosides as potential inhibitors of SARS-CoV-2 main protease: an in silico drug repurposing study on FDA-approved antiviral and anti-infection agents","volume":"14","author":"Ahmed","year":"2021","journal-title":"J Infect Public Health"},{"key":"10.1016\/j.xphs.2023.08.007_bib0004","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11908-018-0614-0","article-title":"Pharmacokinetic and pharmacodynamic considerations of antibiotics of last resort in treating gram-negative infections in adult critically ill patients","volume":"20","author":"Heavner","year":"2018","journal-title":"Curr Infect Dis Rep"},{"key":"10.1016\/j.xphs.2023.08.007_bib0005","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1177\/0885066610377968","article-title":"Management of aminoglycosides in the intensive care unit","volume":"25","author":"Radigan","year":"2010","journal-title":"J Intensive Care Med"},{"key":"10.1016\/j.xphs.2023.08.007_bib0006","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1186\/s13054-020-03159-z","article-title":"Nutrition of the COVID-19 patient in the intensive care unit (ICU): a practical guidance","volume":"24","author":"Thibault","year":"2020","journal-title":"Crit Care Lond Engl"},{"key":"10.1016\/j.xphs.2023.08.007_bib0007","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/jpen.1930","article-title":"Nutrition therapy in critically ill patients with coronavirus disease 2019","volume":"44","author":"Martindale","year":"2020","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"10.1016\/j.xphs.2023.08.007_bib0008","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.jval.2014.02.009","article-title":"A retrospective, observational study of patient outcomes for critically ill patients receiving parenteral nutrition","volume":"17","author":"Magee","year":"2014","journal-title":"Value Health J Int Soc Pharmacoeconomics Outcomes Res"},{"key":"10.1016\/j.xphs.2023.08.007_bib0009","first-page":"E770","article-title":"Clinical nutrition of critically ill patients in the context of the latest ESPEN guidelines","volume":"55","author":"Gosty\u0144ska","year":"2019","journal-title":"Med Kaunas Lith"},{"key":"10.1016\/j.xphs.2023.08.007_bib0010","article-title":"Parenteral fish oil: an adjuvant pharmacotherapy for coronavirus disease 2019?","volume":"81","author":"Torrinhas","year":"2021","journal-title":"Nutr Burbank Los Angel Cty Calif"},{"key":"10.1016\/j.xphs.2023.08.007_bib0011","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1002\/jpen.1871","article-title":"Parenteral fish-oil emulsions in critically ill COVID-19 emulsions","volume":"44","author":"Bistrian","year":"2020","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"10.1016\/j.xphs.2023.08.007_bib0012","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1002\/jpen.1933","article-title":"Response to Bistrian BR. Parenteral fish-oil emulsions in critically ill COVID-19 emulsions","volume":"44","author":"Torrinhas","year":"2020","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"10.1016\/j.xphs.2023.08.007_bib0013","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.jfda.2015.04.004","article-title":"Effect of high-pressure homogenization preparation on mean globule size and large-diameter tail of oil-in-water injectable emulsions","volume":"23","author":"Peng","year":"2015","journal-title":"J Food Drug Anal"},{"key":"10.1016\/j.xphs.2023.08.007_bib0014","doi-asserted-by":"crossref","first-page":"E292","DOI":"10.3390\/pharmaceutics12030292","article-title":"Safe practice of Y-site drug administration: the case of colistin and parenteral nutrition","volume":"12","author":"Stawny","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.xphs.2023.08.007_bib0015","first-page":"2539","article-title":"In vitro compatibility studies of vancomycin with ready-to-use parenteral nutrition admixtures for safer clinical practice","volume":"39","author":"Stawny","year":"2020","journal-title":"Clin Nutr Edinb Scotl"},{"key":"10.1016\/j.xphs.2023.08.007_bib0016","first-page":"1242","article-title":"Physicochemical compatibility and stability of linezolid with parenteral nutrition","volume":"24","author":"Tomczak","year":"2019","journal-title":"Mol Basel Switz"},{"key":"10.1016\/j.xphs.2023.08.007_bib0017","unstructured":"\u3008729\u3009 Globule Size Distribution in Lipid Injectable Emulsions. n.d. 10.31003\/USPNF_M99505_02_01."},{"key":"10.1016\/j.xphs.2023.08.007_bib0018","first-page":"217","article-title":"Toward safe pharmacotherapy: the interplay between meropenem and parenteral nutrition admixtures","volume":"10","author":"Gosty\u0144ska","year":"2021","journal-title":"Antibiot Basel Switz"},{"key":"10.1016\/j.xphs.2023.08.007_bib0019","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1177\/0148607112464239","article-title":"Compatibility of intravenous medications with parenteral nutrition: in vitro evaluation","volume":"37","author":"Bouchoud","year":"2013","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"10.1016\/j.xphs.2023.08.007_bib0020","article-title":"Compatibility of intravenous metronidazole with some all-in-one parenteral nutrition regimens","volume":"84","author":"Dettlaff","year":"2021","journal-title":"Nutr Burbank Los Angel Cty Calif"},{"key":"10.1016\/j.xphs.2023.08.007_bib0021","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12937-016-0149-x","article-title":"Development and evaluation of a test program for Y-site compatibility testing of total parenteral nutrition and intravenous drugs","volume":"15","author":"Staven","year":"2016","journal-title":"Nutr J"},{"key":"10.1016\/j.xphs.2023.08.007_bib0022","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3390\/pharmaceutics14020371","article-title":"Sodium valproate incompatibility with parenteral nutrition admixtures\u2014a risk to patient safety: an in vitro evaluation study","volume":"14","author":"Piwowarczyk","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.xphs.2023.08.007_bib0023","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1177\/0148607189013005505","article-title":"The stability of amikacin, gentamicin, and tobramycin in total nutrient admixtures","volume":"13","author":"Bullock","year":"1989","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"10.1016\/j.xphs.2023.08.007_bib0024","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1093\/ajhp\/52.6.623","article-title":"Physicochemical stability of total nutrient admixtures","volume":"52","author":"Driscoll","year":"1995","journal-title":"Am J Health-Syst Pharm"},{"key":"10.1016\/j.xphs.2023.08.007_bib0025","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1093\/ajhp\/zxaa299","article-title":"Compatibility of medications with intravenous lipid emulsions: Effects of simulated Y-site mixing","volume":"77","author":"Ross","year":"2020","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.xphs.2023.08.007_bib0026","unstructured":"https:\/\/www.hpra.ie\/img\/uploaded\/swedocuments\/Licence_PA2059-058-002_29042020152036.pdf. Accessed 20 June 2023."},{"key":"10.1016\/j.xphs.2023.08.007_bib0027","unstructured":"https:\/\/docetp.mpa.se\/LMF\/Nutriflex%20Omega%20special%20emulsion%20for%20infusion%20ENG%20SmPC_09001bee807a5ec4.pdf. Accessed 20 June 2023."},{"key":"10.1016\/j.xphs.2023.08.007_bib0028","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/0006-2952(84)90319-8","article-title":"Interactions of aminoglycoside antibiotics with negatively charged lipid layers. Biochemical and conformational studies","volume":"33","author":"Brasseur","year":"1984","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.xphs.2023.08.007_bib0029","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3109\/08860229209106642","article-title":"Drug-phospholipid interactions: role in aminoglycoside nephrotoxicity","volume":"14","author":"Kaloyanides","year":"1992","journal-title":"Ren Fail"},{"key":"10.1016\/j.xphs.2023.08.007_bib0030","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202103718","article-title":"Aminoglycoside-based biomaterials: from material design to antibacterial and gene delivery applications","volume":"31","author":"Hu","year":"2021","journal-title":"Adv. Funct. Mater"},{"key":"10.1016\/j.xphs.2023.08.007_bib0031","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.bpj.2014.12.020","article-title":"Electrostatic interactions in aminoglycoside-RNA complexes","volume":"108","author":"Kulik","year":"2015","journal-title":"Biophys J"},{"key":"10.1016\/j.xphs.2023.08.007_bib0032","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1016\/0006-2952(84)90087-X","article-title":"Characterization of aminoglycoside-lipid interactions and development of a refined model for ototoxicity testing","volume":"33","author":"Wang","year":"1984","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.xphs.2023.08.007_bib0033","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1128\/AAC.30.3.395","article-title":"Membrane perturbation by aminoglycosides as a simple screen of their toxicity","volume":"30","author":"Au","year":"1986","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.xphs.2023.08.007_bib0034","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1093\/ajhp\/53.21.2611","article-title":"Compatibility of neonatal parenteral nutrient solutions with selected intravenous drugs","volume":"53","author":"Veltri","year":"1996","journal-title":"Am J Health-Syst Pharm AJHP"},{"key":"10.1016\/j.xphs.2023.08.007_bib0035","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/jac\/dkl489","article-title":"Combined effect of pH and concentration on the activities of gentamicin and oxacillin against Staphylococcus aureus in pharmacodynamic models of extracellular and intracellular infections","volume":"59","author":"Baudoux","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.xphs.2023.08.007_bib0036","unstructured":"Study of the In-vitro antibacterial activity of selected antibiotics and their synergistic interactions with vitamin C against Pseudomonas aeruginosa isolated from different clinical infections n.d.https:\/\/www.teikyomedicaljournal.com\/article\/study-of-the-in-vitro-antibacterial-activity-of-selected-antibiotics-and-their-synergistic-interactions-with-vitamin-c-against-pseudomonas-aeruginosa-isolated-from-different-clinical-infections Accessed 12 April 2023."},{"key":"10.1016\/j.xphs.2023.08.007_bib0037","first-page":"296","article-title":"Ascorbic acid reduces gentamicin-induced nephrotoxicity in rats through the control of reactive oxygen species","volume":"33","author":"Moreira","year":"2014","journal-title":"Clin Nutr Edinb Scotl"},{"key":"10.1016\/j.xphs.2023.08.007_bib0038","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.transproceed.2007.02.038","article-title":"Antioxidant vitamins preserve superoxide dismutase activities in gentamicin-induced nephrotoxicity","volume":"39","author":"Kadkhodaee","year":"2007","journal-title":"Transplant Proc"},{"key":"10.1016\/j.xphs.2023.08.007_bib0039","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0278-6915(03)00186-8","article-title":"Agents ameliorating or augmenting experimental gentamicin nephrotoxicity: some recent research","volume":"41","author":"Ali","year":"2003","journal-title":"Food Chem Toxicol"},{"key":"10.1016\/j.xphs.2023.08.007_bib0040","series-title":"Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids","year":"2000"},{"key":"10.1016\/j.xphs.2023.08.007_bib0041","first-page":"1357","article-title":"ESPEN micronutrient guideline","volume":"41","author":"Berger","year":"2022","journal-title":"Clin Nutr Edinb Scotl"},{"key":"10.1016\/j.xphs.2023.08.007_bib0042","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3390\/pharmaceutics12070677","article-title":"Y-site physical compatibility of numeta G13E with drugs frequently used at neonatal intensive care","volume":"12","author":"Nezvalova-Henriksen","year":"2020","journal-title":"Pharmaceutics"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354923003301?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354923003301?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:41:51Z","timestamp":1758361311000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354923003301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":42,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S0022354923003301"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2023.08.007","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improving the Safety of Clinical Management of COVID-19 Patients Receiving Aminoglycosides and Parenteral Nutrition: Y-site Compatibility Studies","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2023.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 American Pharmacists Association. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}